Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Medicare, ESRD Bundle, H.R.5074, S.4510, Kidney Patient Act
Medicare, ESRD Bundle, H.R.5074, S.4510, Kidney Patient Act
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
ARDELYX, INC. via ARDELYX, INC.
2026 · second_quarter · 2A
Access to innovative medications for people with kidney failure; reimbursement; drug pricing; most favored nation drug pricing; Medicare kidney care access and payment issues.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ARDELYX, INC. via ARDELYX, INC.
2026 · second_quarter · Q2
Source: Senate LDA
H.R.5074, S.4510, Kidney Patient Act, Kidney Health Equity. Access to Innovative Kidney Treatments.
Medicare, ESRD Bundle, H.R.5074, S.4510, Kidney Patient Act
Medicare, ESRD Bundle, H.R.5074, S.4510, Kidney Patient Act
Medicare, ESRD Bundle, H.R.5074, S.4510, Kidney Patient Act
H.R.5074, S.4510, Kidney Patient Act, Kidney Health Equity. Access to Innovative Kidney Treatments.
Medicare, ESRD Bundle, H.R.5074, S.4510, Kidney Patient Act
Access to innovative kidney treatments. H.R.5074 - Protecting Young Minds Online Act, S.4510 - Kidney PATIENT Act of 2024. Pharmaceutical pricing proposals, Medicare pharmaceutical payment and access issues. Coverage of oral only End-Stage Renal Disease drugs.
Access to innovative kidney treatments. H.R.5074 - Protecting Young Minds Online Act, S.4510 - Kidney PATIENT Act of 2024. Pharmaceutical pricing proposals, Medicare pharmaceutical payment and access issues. Coverage of oral only End-Stage Renal Disease drugs.
H.R.5074 - Kidney Patient Access to Technologically Innovative and Essential Nephrology Treatments Act of 2023 - To delay incorporation of oral drugs indicated for the reduction, management, or control of the serum phosphate of an individual into the End-Stage Renal Disease (ESRD) Prospective Payment System. S.4510 - A bill to amend the American Taxpayer Relief Act of 2012 to delay implementation of the inclusion of oral-only ESRD-related drugs in the Medicare ESRD prospective payment system.
H.R.5074 - Kidney Patient Access to Technologically Innovative and Essential Nephrology Treatments Act of 2023 - To delay incorporation of oral drugs indicated for the reduction, management, or control of the serum phosphate of an individual into the End-Stage Renal Disease (ESRD) Prospective Payment System. S.4510 - A bill to amend the American Taxpayer Relief Act of 2012 to delay implementation of the inclusion of oral-only ESRD-related drugs in the Medicare ESRD prospective payment system.
H.R.5074 - Kidney Patient Access to Technologically Innovative and Essential Nephrology Treatments Act of 2023 - To delay incorporation of oral drugs indicated for the reduction, management, or control of the serum phosphate of an individual into the End-Stage Renal Disease (ESRD) Prospective Payment System. S.4510 - A bill to amend the American Taxpayer Relief Act of 2012 to delay implementation of the inclusion of oral-only ESRD-related drugs in the Medicare ESRD prospective payment system.
H.R.5074 - Kidney Patient Access to Technologically Innovative and Essential Nephrology Treatments Act of 2023 - To delay incorporation of oral drugs indicated for the reduction, management, or control of the serum phosphate of an individual into the End-Stage Renal Disease (ESRD) Prospective Payment System. S.4510 - A bill to amend the American Taxpayer Relief Act of 2012 to delay implementation of the inclusion of oral-only ESRD-related drugs in the Medicare ESRD prospective payment system.
Access to innovative medications for people with kidney failure; reimbursement; drug pricing; most favored nation drug pricing; Medicare kidney care access and payment issues.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ARDELYX, INC. via ARDELYX, INC.
2026 · first_quarter · Q1
Access to innovative kidney treatments, ESRD PPS, coverage of oral only medications for people with ESRD, innovation, Drug pricing, Medicare access to pharmaceuticals.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ARDELYX, INC. via ARDELYX, INC.
2025 · third_quarter · Q3
Access to innovative kidney treatments. H.R.5074 - Protecting Young Minds Online Act, S.4510 - Kidney PATIENT Act of 2024. Pharmaceutical pricing proposals, Medicare pharmaceutical payment and access issues. Coverage of oral only End-Stage Renal Disease drugs.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ARDELYX, INC. via ARDELYX, INC.
2025 · first_quarter · 1A
Medicare, ESRD Bundle, H.R.5074, S.4510, Kidney Patient Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ARDELYX, INC. via ARDELYX, INC.
2025 · first_quarter · 1A
Medicare, ESRD Bundle, H.R.5074, S.4510, Kidney Patient Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ARDELYX, INC. via ARDELYX, INC.
2025 · second_quarter · Q2
H.R.5074, S.4510, Kidney Patient Act, Kidney Health Equity. Access to Innovative Kidney Treatments.
Filing targets: HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE
ARDELYX, INC. via ARDELYX, INC.
2025 · first_quarter · Q1
Medicare, ESRD Bundle, H.R.5074, S.4510, Kidney Patient Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ARDELYX, INC. via ARDELYX, INC.
2024 · fourth_quarter · Q4
H.R.5074 - Kidney Patient Access to Technologically Innovative and Essential Nephrology Treatments Act of 2023 - To delay incorporation of oral drugs indicated for the reduction, management, or control of the serum phosphate of an individual into the End-Stage Renal Disease (ESRD) Prospective Payment System. S.4510 - A bill to amend the American Taxpayer Relief Act of 2012 to delay implementation of the inclusion of oral-only ESRD-related drugs in the Medicare ESRD prospective payment system.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
ARDELYX, INC. via ARDELYX, INC.
2024 · third_quarter · Q3
H.R.5074 - Kidney Patient Access to Technologically Innovative and Essential Nephrology Treatments Act of 2023 - To delay incorporation of oral drugs indicated for the reduction, management, or control of the serum phosphate of an individual into the End-Stage Renal Disease (ESRD) Prospective Payment System. S.4510 - A bill to amend the American Taxpayer Relief Act of 2012 to delay implementation of the inclusion of oral-only ESRD-related drugs in the Medicare ESRD prospective payment system.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE